Predictive biomarkers in lymphoma: a systematic research review
DOI:
https://doi.org/10.56183/iberojhr.v4is.614Palavras-chave:
lymphoma. biomarkers. epigenetics. genetics. miRNA. lncRNA. immunophenotype. diagnosis. prognosis. therapeutic targeting.Resumo
Lymphoma is a diverse group of blood cancers originating in the lymphatic system, with varying clinical presentations and prognoses. Identifying and utilizing predictive biomarkers in lymphoma can significantly impact the management and outcome of patients. For instance, the presence of the BCL2 gene rearrangement in follicular lymphoma is associated with a poorer prognosis, while the expression of the CD20 protein in diffuse large B-cell lymphoma is a predictor of response to rituximab. These biomarkers are molecular or cellular indicators that can help forecast disease progression, therapeutic response, and patient prognosis. This abstract provides an overview of the current landscape of predictive biomarkers in lymphoma, focusing on their role which can help physicians to build personalized treatment strategies. We explore key types of biomarkers, including genetic mutations, protein expressions, and cellular markers, that have shown potential in predicting treatment response and survival outcomes across different lymphoma subtypes. Furthermore, we delve into recent advancements in biomarker discovery through high-throughput technologies such as next-generation sequencing and their strategic integration into clinical practice. The use of predictive biomarkers not only enhances the precision of treatment regimens but also contributes to better risk stratification and patient monitoring. The future of this field involves the refinement of biomarker panels for improved predictive accuracy and the exploration of novel targets for therapy. The strategic application of predictive biomarkers in lymphoma presents promising opportunities for optimizing patient care and advancing precision medicine in hematological malignancies.
Referências
Lymphoma - Symptoms and causes - Mayo Clinic. (2022, December 14). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/lymphoma/symptoms-causes/syc-20352638
Lymphoma - Hodgkin - statistics. (2023, May 25). Cancer.Net. https://www.cancer.net/cancer-types/lymphoma-hodgkin/statistics
How Common is Lymphoma? | Key Statistics for Non-Hodgkin Lymphoma. (n.d.). American Cancer Society. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A., & Bhat, A. A. (2024). Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Translational Oncology, 39, 101821. https://doi.org/10.1016/j.tranon.2023.101821
Swerdlow SH, Campo E, Harris NL et alWorld Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. LARK: Lyon, 2008.
Iqbal J, Shen Y, Huang X et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood 2015;125:1137–1145.
Wang, H., Liu, Z., & Zhang, G. (2020). FBN1 promotes DLBCL cell migration by activating the Wnt/β-catenin signaling pathway and regulating TIMP1. American journal of translational research, 12(11), 7340–7353.
Lai, P., & Wang, Y. (2021). Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biology & Medicine, 18(1), 34–51. https://doi.org/10.20892/j.issn.2095-3941.2020.0216
Sermer, D., Pasqualucci, L., Wendel, H., Melnick, A., & Younes, A. (2019). Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews. Clinical Oncology, 16(8), 494–507. https://doi.org/10.1038/s41571-019-0190-8
Sun, R., Medeiros, L. J., & Young, K. H. (2016). Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Modern Pathology, 29(10), 1118–1142. https://doi.org/10.1038/modpathol.2016.92
Kos, I. A., Thurner, L., Bittenbring, J. T., Christofyllakis, K., & Kaddu‐Mulindwa, D. (2021). Advances in lymphoma Molecular Diagnostics. Diagnostics, 11(12), 2174. https://doi.org/10.3390/diagnostics11122174
Sun, R., Medeiros, L. J., & Young, K. H. (2016). Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Modern Pathology, 29(10), 1118–1142. https://doi.org/10.1038/modpathol.2016.92
Akay, O. M., Aras, B. D., Işıksoy, S., Toprak, Ç., Mutlu, F., Artan, S., Öner, Ü., & Gülbaş, Z. (2014). BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients. Cancer Genetics, 207(3), 87–93. https://doi.org/10.1016/j.cancergen.2014.02.001
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M., Valeri, N., & Hahne, J. C. (2020). MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Targeted Oncology, 15(3), 261–278. https://doi.org/10.1007/s11523-020-00717-x
Bertoli, G., Cava, C., & Castiglioni, I. (2015). MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics, 5(10), 1122–1143. https://doi.org/10.7150/thno.11543
Mazan-Mamczarz, K., & Gartenhaus, R. B. (2013). Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leukemia Research, 37(11), 1420–1428. https://doi.org/10.1016/j.leukres.2013.08.020
García-Domínguez, D. J., Hontecillas‐Prieto, L., Palazón‐Carrión, N., Jiménez‐Cortegana, C., Sánchez‐Margalet, V., & De La Cruz‐Merino, L. (2022). Tumor immune microenvironment in lymphoma: Focus on Epigenetics. Cancers, 14(6), 1469. https://doi.org/10.3390/cancers14061469
Fowler, N., Cheah, C. Y., Gascoyne, R. D., Gribben, J. G., Neelapu, S. S., Ghia, P., Bollard, C. M., Ansell, S. M., Curran, M. A., Wilson, W. H., O’Brien, S., Grant, C., Little, R. F., Zenz, T., Nastoupil, L. J., & Dunleavy, K. (2016). Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 101(5), 531–540. https://doi.org/10.3324/haematol.2015.139493
Sun, R., Medeiros, L. J., & Young, K. H. (2016). Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. *Modern Pathology*, *29*(10), 1118–1142. doi:10.1038/modpathol.2016.166
Ingravallo, G., Tamma, R., Opinto, G., Annese, T., Gaudio, F., Specchia, G., Perrone, T., Musto, P., Cazzato, G., Bellitti, E., Capodiferro, S., Maiorano, E., & Ribatti, D. (2022). The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells. Diagnostics, 12(3), 573. https://doi.org/10.3390/diagnostics12030573
Syrykh, C., Abreu, A., Amara, N., Siegfried, A., Maisongrosse, V., Frenois, F. X., Martin, L., Rossi, C., Laurent, C., & Brousset, P. (2020). Accurate diagnosis of lymphoma on whole-slide histopathology images using deep learning. Npj Digital Medicine, 3(1). https://doi.org/10.1038/s41746-020-0272-0
Ali, S., Rathore, Z., Jahangir, F., Rafique, Z., Chughtai, A. S., & Atiq, A. (2022). Expression of C-MYC, BCL2, BCL6, and cyclin D1 in High-Grade B-Cell lymphoma. Curēus. https://doi.org/10.7759/cureus.29527
Xu‐Monette, Z. Y., Zhang, S., Li, X., Manyam, G. C., Wang, X. X., Xia, Y., Visco, C., Tzankov, A., Zhang, L., Montes‐Moreno, S., Dybkær, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K. L., Hsi, E. D., Choi, W. W., Van Krieken, J. H., . . . Young, K. H. (2016). p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 8(2), 345–365. https://doi.org/10.18632/aging.100898
Rimsza LM, Chan WC, Gascoyne RD et al. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009;94:596–598
Honma K, Tsuzuki S, Nakagawa M et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467–2475
Friedberg JW . Double-hit diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3439–3443.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Román Rolando Lima Cajas, Gabriela Fernanda Panchi Espin, Robert Adan Lalama Rueda, Juan Esteban Lalama Rueda, Freddy Leonardo Pavón Patiño, Mayra Katherine Quincha Muñoz
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
